XenoPort, Inc. To Present New Data Analyses For HORIZANT (gabapentin enacarbil) At The 67th Annual Meeting Of The American Academy of Neurology

SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq:XNPT) announced today that it will present pooled post-hoc analyses for gabapentin enacarbil, the active ingredient in HORIZANT® (gabapentin enacarbil) Extended-Release Tablets, at the upcoming 67th Annual Meeting of the American Academy of Neurology in Washington, DC.

Help employers find you! Check out all the jobs and post your resume.